1 September 2018 in Nature and Science of Sleep
For individuals with Down syndrome (DS), obstructive sleep apnea (OSA) is a complex disorder with significant clinical consequences. OSA is seen frequently in DS, and when present, it tends to be more severe. This increased prevalence is likely related to common anatomic abnormalities and a greater risk of additional comorbidities such as hypotonia and obesity. Because signs and symptoms do not often correlate with disease, all children and adults with DS should receive routine screening for OSA. Similar to the general population, polysomnography remains the gold standard for diagnosis. Because individuals with DS may be more susceptible to cardiovascular and neurocognitive sequelae, early diagnosis and treatment of OSA is becoming increasingly important. Treatment options generally involve upper airway surgery (primarily adenotonsillectomy) and continuous positive airway pressure (CPAP); however, various adjunctive therapies including intranasal steroids, palatal expansion, and oropharyngeal exercises are also available. Residual disease status post adenotonsillectomy is common, and further evaluation (eg, drug-induced sleep endoscopy [DISE]) is often needed. More advanced and directed airway surgery can be performed if additional sites of obstruction are observed. Novel therapies including hypoglossal nerve stimulation are emerging as effective treatments for refractory OSA. Due to the diversity among individuals with DS, personalized treatment plans should be developed. Within this arena, opportunities for research remain abundant and should include areas involving patient risk factors, alternative diagnostic methods, and outcome analysis.
8 February 2023 in Pediatric Pulmonology
21 May 2025 in Pediatric Pulmonology
Introduction: The Pediatric Mechanical Ventilation Society is a collaboration of pediatric pulmonologists with a focus on pediatric chronic home invasive ventilation (PCHIV). Since the initial discharge on PCHIV is not always directed by pediatric pulmonologists, we sought to understand how this variability between centers impact adherence to American Thoracic Society (ATS) guidelines for PCHIV. Methods: A survey was distributed to pediatric pulmonologists across multiple platforms inquiring about discharging practices for PCHIV and adherence to six of the nine ATS recommendations for PCHIV. Two subgroups were created based on common practices — discharge by pediatric pulmonologists from a non‐ICU unit (pulmonary group) and discharge by ICU team from an ICU unit (ICU group). Results: A total of 107 surveys were completed, 90 from the US. Among the US centers, the ATS recommendations with lowest adherence were offering ongoing education to caregivers and the utilization of standardized criteria for discharge. Despite better adherence, the requirement of two caregivers for discharge was often made an exception for. When comparing the pulmonary and ICU groups, the number of annual discharges ( p < 0.001), caregiver length of training ( p = 0.003), and the utilization of standardized discharge criteria ( p = 0.04) were significantly different. Discussion: Our study demonstrates variable adherence to expert consensus recommendations outlined by the ATS. A significant proportion of PCHIV patients were discharged directly from the ICU and by ICU teams. Practice variability was evident between institutions and discharging teams; therefore, the identification of barriers to guideline implementation and multidisciplinary collaboration is paramount to optimizing care.
30 July 2024 in Pediatric Pulmonology
4 July 2022 in Pediatric Pulmonology
14 May 2024 in Pediatric Pulmonology
TSThe Pediatric Mechanical Ventilation Society
The Pediatric Mechanical Ventilation Society
+1